{"id":24158,"date":"2024-05-28T11:58:50","date_gmt":"2024-05-28T09:58:50","guid":{"rendered":"https:\/\/idibell.cat\/en\/?p=24158"},"modified":"2024-05-28T11:58:50","modified_gmt":"2024-05-28T09:58:50","slug":"the-viii-barcelona-fire-brigade-solidarity-nautical-mile-2024-will-support-research-into-the-rare-disease-lam","status":"publish","type":"post","link":"https:\/\/idibell.cat\/en\/2024\/05\/the-viii-barcelona-fire-brigade-solidarity-nautical-mile-2024-will-support-research-into-the-rare-disease-lam\/","title":{"rendered":"The VIII Barcelona Fire Brigade Solidarity Nautical Mile 2024 will support research into the rare disease LAM"},"content":{"rendered":"
The Cultural and Sports Association of Barcelona Firefighters organizes the VIII Barcelona Firefighters Solidarity Nautical Mile, which this year will raise funds for the Spanish Association of Lymphangioleiomyomatosis (AELAM). The aim is to continue advancing research to improve diagnosis and find a treatment for this rare disease that currently has no cure.<\/p>\n
Lymphangioleiomyomatosis (LAM) is a rare disease of unknown origin and difficult to diagnose that mainly affects women of childbearing age. It is characterized by causing an abnormal growth of cells in the lungs, generating a pathology that destroys the organ with slow but continuous progression. There is no cure for LAM, but there is a drug called rapamycin that, in most cases, slows down the progress of the disease. If medication is unsuccessful, a full lung transplant must be used.<\/p>\n
The AELAM Association supports LAM research<\/strong> led by Dr. Miquel \u00c0ngel Pujana<\/strong>, principal investigator of the Breast Cancer and LAM research group at IDIBELL, IDIBGI and the Catalan Institute of Oncology (ICO). “Our research seeks to identify biomarkers that facilitate the non-invasive diagnosis of this rare disease,” says Dr. Pujana, who adds: “in parallel, we are also investigating to find targeted therapies that allow LAM cells to be completely eliminated in patients.”<\/p>\n AELAM has been collaborating with this research group for nearly 10 years<\/strong> now: “We are deeply grateful for the AELAM Association’s continued support of our research in LAM. The involvement of patients in funding and their support for research are fundamental pillars that drive the translation of our discoveries into tangible advances in the cure of this disease,” says Dr. Pujana.<\/p>\n Four Mile Categories 2024<\/strong><\/p>\n